Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETS6103 vs Amitriptyline in SSRI-resistant Major Depressive Disorder
NCT02014363Phase 2Completed
- Sponsor
- e-therapeutics plc
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ETS6103 in major depressive disorder (MDD), sponsored by e-therapeutics plc. Started Oct 2013; status: completed.
02
Drugs
ETS6103
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02014363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014363.